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The antigen receptor expressed on most thymocytes and mature T lympho-
cytes is a C133-associated disulfide-linked heterodimer composed of a and (3
subunits (1). A minor population ofCD3+ thymocytes and T cells lack expression
ofthe TCR-a/0 (2-4), but instead expressa TCR-y that is often either covalently
or noncovalently associated with TCR-b (2-10). Some IL-2-dependent T cell
lines expressing TCR-7/6 mediate cytotoxicity against a broad panel of tumor
cell targets (7-9). The generation of cytotoxicity does not require deliberate
immunization and is not restricted by the MHC. Although these studies clearly
indicate that T cells expressing TCR-y/b possess the cellular machinery to
mediate cytotoxicity, it is unclear whether the broad spectrum of cytotoxicity
mediated by these cells in vitro reflects their activity in vivo, or alternatively, if
this results from in vitro culture. Cytotoxicity mediated by some CD3, y/b T cell
lines is partially inhibited by anti-CD3 antibodies (7-9). However, antibodies
against CD3 may influence the function of a cell by a mechanism other than
interfering with antigen recognition. We have established IL-2-dependent cell
lines from thymocytes expressing either TCR-a/fl or -y/b and have undertaken
studies to determine whether the TCR is necessary for cytotoxic function.
Materials and Methods
Cell Lines.
￿
Normal human thymocytes were cultured as described (5). After 2-3 wk,
cells were stained with FITC-conjugated WT31 and PE-conjugated anti-Leu-4 (CD3) (5).
CD3+,WT3I' and CD3+,WT31- thymocytes (hereafter referred to as C133-a/0 and CD3-
y/b thymocytes, respectively) were isolated to >98% purity using a FACS and were
maintained as IL-2-dependent cell lines. KW antiJY CTL is an IL-2-dependent CD3-
a/0,CD8' CTL cell line directed against HLA-A2 (11).
Antibodies.
￿
WT31 reacts with a framework determinant on the TCR-a/0 (11). W6/32
hybridoma (IgG2a mAb directed against a monomorphic epitope expressed on HLA-
A,B,C) was obtained from the American Type Culture Collection (Rockville, MD). F(ab')2
fragments were prepared by pepsin digestion (12).
Modulation.
￿
Modulation was performed as described (13). Briefly, cells were cultured
overnight in the presence or absence of anti-Leu-4 mAb. After modulation, cells were
washed extensively and were stained by indirect immunofluorescence with IgGI control
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FIGURE 1 .
￿
Cytotoxicity mediated by CD3-a/# and CD3-,y/b thymic cell line.
mAb or anti-Leu-4, followed by FITC goat anti-mouse Ig. Cells were analyzed by flow
cytometry.
Cytotoxicity Assays.
￿
Cytotoxicity was measured using a 4-h radioisotope release assay
(14). In antibody-blocking assays, effector cells were incubated at 37° C for 3 h with
antibodies before the addition of targets. Antibody-dependent, cell-mediated cytotoxicity
(ADCC) assays were performed using JY cells precoated with anti-HLA mAb (W6/32)
(15).
Results and Discussion
Culture of thymocytes in IL-2 results in the rapid generation of non-MHC-
restricted CTL, whereas before culture thymocytes do not mediate cytotoxicity
(16-19). We have compared IL-2-dependent CD3-y/b and CD3-a/# thymic cell
lines established from three different individuals for their ability to mediate non-
MHC-restricted cytotoxicity and ADCC. Neither the CD3-y/b nor CD3-a/#
thymic cell lines mediated ADCC activity (Fig. 1), consistent with the absence of
Fc receptors (CD 16) on these cells (not shown). However, both the CD3-'y/b and
CD3-a/# thymic cell lines lysed an erythroleukemia cell line (K562), a B lympho-
blastoid cell line (JY), a colon carcinoma cell line (COLO-205), and a fresh,
noncultured sarcoma. Both IL-2-cultured TCR-a/,B- and TCR-,y/6-bearing thy-
mocytes established from the same individuals and grown under identical culture
conditions acquired the ability to lyse hematopoietic and solid tumor cell targets
without MHC restriction. Moreover, note that both the magnitude and spectrum
of target lysis mediated by both the TCR-a/# and TCR-y/b thymic cell lines are
essentially identical, even though there was no deliberate immunization or
selection for cytotoxic activity against these targets. It seems unlikely that an
essentially identical repertoire of cytolytic activity would be observed if the TCR-
a/S or TCR-y/b antigen receptors are responsible for specific antigen recogni-
tion. This observation suggests the possibility that a cell surface receptor, other
than the TCR, may be responsible for target recognition and cytolysis.No Mab
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It has been observed that anti-CD3 antibodies can induce CD3-'Y/S cell lines
(5-8), as well as alloantigen-specific CTL cell lines (20), to nonspecifically lyse
targets expressing Fc receptors. We have previously demonstrated that intact
anti-Leu-4 mAb can induce CD3-1'/S T cell lines established from normal
peripheral bloodto nonspecificallylyseJY, a B lymphoblastoid cell line expressing
Fcreceptors for IgG1 (21). However, intact anti-Leu-4 did not induce nonspecific
lysis by either the CD3-y/S or CD3-a/# thymic cell lines (Fig. 2). As a positive
control for anti-CD3-induced lysis, we demonstrate that anti-Leu-4 induced an
alloantigen-specific CTL cell line to nonspecifically lyse K562. These findings
indicate that in contrast to CD3-,y/b PBL/T cell lines and conventional antigen-
specific CD3-a/# CTL cell lines, these thymic cell lines did not mediate anti-
C133-induced cytotoxicity. Thus, the CD3/TCR complex on the plasma mem-
brane of these thymic cells lines may not be capable of activating the cytolysic
mechanism.
Further studies were undertaken to determine whether cytotoxicity could be
inhibited by antibodies against CD3 and CD2. F(ab')2 fragments of anti-Leu-4
(CD3) or anti-Leu-5b (CD2) did not inhibit the cytolysis mediated by either the
CD3-'Y/S orCD3-a/fl thymic cell lines (Fig. 2). Cytotoxicity was inhibitedby anti-
CD18 (LFA-1,B) mAb (not shown). However, consistent with prior reports, anti-
CD3 and anti-CD2 did substantially inhibit the cytolysis mediated by an alloan-
tigen-specific CTL cell line.
Overnight culture of CD3-,y/b and CD3-a/# thymic cell lines in the presence
of F(ab')2 fragments of anti-Leu-4 (CD3) resulted in substantial modulation of
CD3. Quantitation by flow cytometry indicated that >99% of the CD3 antigen
was removed from the cell surface ofthe C]33-'Y/S and CD3-a/#thymic cell lines
(Fig. 3). However, modulation ofCD3 failed to inhibit cytotoxicity mediated by
either the CD3-,y/b or CD3-a/# thymic cell lines, even though saturating concen-
trations ofanti-CD3 were also present throughout the cytotoxicity assay (Fig. 4).
The inability to inhibit cytotoxic function of the CD3-,y/b and CD3-a/# thymic1582
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FIGURE 4 . Cytotoxicity after mod-
ulation of CD3. CD3- ,y/b and CD3-
a/# thymic cells were cultured over-
night in the absence (not modulated)
or presence (modulated) of anti-Leu
4 (Fig. 3) . Modulatedthymic effector
cells were incubated at 37°C for 3 h
with F(ab')2 fragments of anti-Leu-4
(5 wg/ml) before the addition of tar-
gets .
cell lines by anti-CD3 mAb or by modulation ofCD3 further questions whether
theTCR is responsible for target recognition and signal transduction .
Cytotoxicity mediated by some CD3-,y/b T cell lines established from periph-
eral blood is partially inhibited by anti-CD3 antibodies (7-9) . These discrepant
findings may reflect the origin of these cell lines, i.e ., thymus versus peripheral
blood . Alternatively, the assay conditions used for blocking may differ . In prior
studies, ascites rather than purified mAb was used for inhibition (7-9). It should
be noted that data from antibody inhibition experiments must be cautiously
interpreted, particularly when using high antibody concentrations . Antibodies
against CD2, CD4, CD8, CD1la (LFA-1a), CD18 (LFA-If), and CD45 (T200)
can inhibit cytotoxicity mediated by conventional antigen-specific, MHC-re-
stricted CTL ; however, these structures are not the antigen receptor .
Non-MHC-restricted cytotoxicity can be mediated by both NK cells and
certain T lymphocytes (22) . NK cells do not express CD3, and rearrange neither
TCR-,Q nor TCR-y genes (22-24) . In contrast, IL-2-dependent non-MHC-
restricted CTL can express either a/# or y/b antigen receptors (7-9, 22) . Thus,
the phenomenon of non-MHC-restricted recognition and cytotoxicity is not
exclusively mediated by a single type of effector . NK cells, as well as CD3-y/b-
and CD3-a/l3-bearingT cell lines, recognize and kill a similar spectrum oftumor
cell targets . Results from our present studies indicate that some CD3-a/(3 and
CD3- ,y/b thymocytes may not mediate cytotoxicity via the CD3/TCR complex.
These observations suggest that NK cells and some non-MHC-restricted CTL
may mediate cytotoxicity by a common target recognition structure other than
theTCR.
In conclusion, the only evidence that CD3-y/b T cells recognize target andPHILLIPS ET AL.
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mediate non-MHC-restricted cytotoxicity via the TCR-7/6 is based on blocking
with anti-CD3 . Since we have demonstrated that cytotoxicity mediated by both
CD3-y/b and CD3-a/#thymic cell lines is not affected by modulation ofthe CD3
complex and is not inhibited by saturating concentrations of purified, F(ab')2
anti-CD3, these resultsindicate that the CD3/TCR complex may not be required
for cytotoxicity. Therefore, the possibility that cytotoxicity is mediated by a
receptor other than the TCR must be considered until there is formal proofby
genetic reconstitution that the TCR-y/b or -a//3 is necessary for non-MHC-
restricted cytotoxicity.
Summary
After culture in IL-2, thymocytes expressing either TCR-a/# or -y/b acquired
the ability to lyse hematopoietic and solid tumor cell targets without deliberate
immunization or apparent restriction by the MHC. Moreover, TCR-a/,B- and
TCR-y/b-bearingthymic cell lines demonstrated an essentially identical spectrum
of cytolysis against several tumor cell targets. Cytotoxicity was not inhibited by
antibodies against CD3 or CD2 and modulation of the CD3/TCR complex also
failed to affect cytotoxicity. Thus, non-MHC-restricted cytotoxicity can be
mediated by thymocytes with either TCR-a/,0 or TCR-y/b, but the TCR may
not be responsible for target recognition.
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